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Abstract
Background: The MASS IV-DM Trial is a large project from a single institution, the Heart Institute (InCor), University
of São Paulo Medical School, Brazil to study ventricular function and coronary arteries in patients with type 2
diabetes mellitus.
Methods/Design: The study will enroll 600 patients with type 2 diabetes who have angiographically normal
ventricular function and coronary arteries. The goal of the MASS IV-DM Trial is to achieve a long-term evaluation of
the development of coronary atherosclerosis by using angiograms and coronary-artery calcium scan by electron-
beam computed tomography at baseline and after 5 years of follow-up. In addition, the incidence of major
cardiovascular events, the dysfunction of various organs involved in this disease, particularly microalbuminuria and
renal function, will be analyzed through clinical evaluation. In addition, an effort will be made to investigate in
depth the presence of major cardiovascular risk factors, especially the biochemical profile, metabolic syndrome
inflammatory activity, oxidative stress, endothelial function, prothrombotic factors, and profibrinolytic and platelet
activity. An evaluation will be made of the polymorphism as a determinant of disease and its possible role in the
genesis of micro- and macrovascular damage.
Discussion: The MASS IV-DM trial is designed to include diabetic patients with clinically suspected myocardial
ischemia in whom conventional angiography shows angiographically normal coronary arteries. The result of
extensive investigation including angiographic follow-up by several methods, vascular reactivity, pro-thrombotic
mechanisms, genetic and biochemical studies may facilitate the understanding of so-called micro- and
macrovascular disease of DM.
Background
Diabetes mellitus is a potentially serious disease and is
currently the major concern of public health officials. This
d i s e a s eh a sap r e v a l e n c eo f2 %t o5 %i nm o s tW e s t e r n
countries and has grown exponentially around the
world, possibly because of changing dietary habits in
recent years [1-3].
Patients with type 2 diabetes often have cardiovascular
risk factors that may further influence the prognosis of the
disease. These risk factors compose metabolic syndrome.
They include high blood pressure [4,5], dyslipidemia, and
obesity, which have been reported as participating in the
pathogenesis of cardiovascular events by possible action
on coronary endothelial function [5]. Moreover, the high
rate of urinary albumin excretion has been hypothesized
as an additional indicator of endothelial dysfunction, which
is associated with a higher rate of renal and cardiovascular
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any medium, provided the original work is properly cited.events [6]. Other risk factors include potential age and
sex [7], smoking [8], glycemic control, lipids [5,9], and
hormone replacement therapies [10].
Major studies have shown that healthy endothelium
inhibits adhesion of platelets and leukocytes to the ves-
sel surface and maintains the balance of profibrinolytic
and prothrombotic activity [11]. However, with the
occurrence of dysfunction, the endothelium is a poten-
tial contributor to the pathogenesis of vascular disease
in diabetes mellitus and atherosclerosis [12].
Under physiological conditions, there is a delicate and
balanced release of relaxing factors and endothelium-
derived contraction factors that apparently is imbalanced
in diabetes and may contribute to the development of
atherosclerosis, thus contributing to the further progres-
sion of vascular injury in different organs [13].
Hyperglycemia has been implicated as the main causal
factor in the development of coronary atherosclerosis in
diabetic patients. However, the mechanisms associated
with this disorder are likely to be multifactorial. Among
these are hypertension, abdominal obesity, and pluri-
metabolic syndrome [14-16].
Besides these, we highlight the presence of decreased
high-density lipoprotein and elevated low-density lipopro-
tein (LDL) cholesterol, high triglycerides, increased VLDL,
nephropathy, altered coagulation, and platelet dysfunction.
Insulin resistance, another existing condition in diabetes,
has been described as responsible for the increased risk of
death from coronary artery disease (CAD) [15-17].
It is assumed that the prevalence of coronary artery
disease (CAD), recognized by a variety of diagnostic
methods, is estimated to be 55% in individuals with
diabetes. This contrasts with 2% to 4% of people with
diabetes in the general population [18]. Patients with
CAD without diabetes compared with those with dia-
betes have coronary atherosclerosis that is more
advanced, with higher rates of ventricular dysfunction
and cardiac events [18-20]. Additionally, the prognosis
of CAD is less favorable in patients with diabetes than
in their nondiabetic counterparts; mortality after
infarction is higher in diabetic patients and is particu-
larly high among women [19-22]. Often, patients with
diabetes may have asymptomatic CAD. In such cases,
t h ef i r s ts i g no fC A Dm a yb et h eo c c u r r e n c eo fam y o -
cardial infarction or cardiac death [21,23]. Data
reported by Haffner [24] show that patients with
diabetes but without CAD have the same incidence
of heart attack as nondiabetic patients with CAD.
Furthermore, 79% of patients with diabetes die of car-
diac complications after an acute myocardial infarction
(AMI) [23]. Moreover, in patients referred to surgery,
the need for new CABG or PCI is significantly higher
in subjects with diabetes than in those without the dis-
ease [25]. This condition led the National Cholesterol
Education Program (NCEP) to consider diabetes as a
risk equivalent to that of CAD [26].
However, although the occurrence of diabetes is a
major determinant of vascular lesions, a small series of
retrospective studies have addressed endothelial behavior
in diabetic patients with angiographically normal coron-
ary arteries [27-29]. On the other hand, few studies have
been directed at discussing in depth the occurrence of
major cardiovascular events in long-term follow-up in
patients with type 2 diabetes mellitus who have angiogra-
phically normal coronary arteries. So, our hypothesis is
that some diabetic patients despite of absence of coron-
ary artery based on angiographic criteria will present
cardiovascular events and progression of the CAD dis-
ease but others won’t along five-years of follow-up. The
main aim of the MASS IV DM study is to identify what is
the protective mechanism of vascular involvement on
this group of diabetes patients and the correlation with
cardiovascular events.
The objectives of the MASS IV-DM Trial is to compare
the clinical data, laboratory profile, and angiographic evo-
lution at baseline with that at 5-year follow-up in patients
with type 2 diabetes who have angiographically normal
coronary arteries.
Methods/Design
The MASS IV-DM Trial is an institutional project to be
conducted at the Heart Institute (InCor), Hospital das
Clinicas, University of São Paulo, and is designed to pro-
spectively investigate 600 type 2 diabetic patients with a
clinical suspicion of coronary insufficiency and electro-
cardiographic evidence of myocardial ischemia who have
normal coronary angiographies and ventricular function.
It is designed as a secondary prospective cohort study.
Only patients with angiographically normal coronary
arteries (by semi quantitative TCA equal to zero) will be
included in the study. After inclusion, all patients will
undergo a 320-row multidetector computed tomography
(MDCT) angiography of the coronary arteries to assess
the calcium score as well as the plaque characteristics if
present any. Both angiography studies will be repeated
after 5 years of follow-up. Ischemia induced by stress
electrocardiography and associated with myocardial
nuclear scintigraphy will be performed at the beginning
and end of the study. Furthermore, ventricular function
will be measured by echocardiography at baseline, and
vascular reactivity and endothelial function will be
recorded at the beginning and end of the study. Labora-
tory tests will include a biochemical profile of blood
lipids, renal function, urinalysis, genetic polymorphism,
oxidative stress, and inflammatory activity, among
others. All patients will undergo an outpatient clinical
evaluation every 6 months. The schedule of activities is
shown in Table 1.
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Page 2 of 7The MASS IV-DM Trial has an independent external
committee that is blind to the clinical evaluation and
will monitor the research. This external committee will
analyze all clinical events including myocardial infarc-
tion, cerebrovascular events, and others. The role of this
committee will be to ensure that clinical events will be
assessed uniformly.
Patients
Diabetic patients with clinically suspected (based on pre-
sence of the CCS II/III angina) or documented myocar-
dial ischemia based on ET will undergo coronary
angiography that will be performed according to the
technique of Sones or Seldinger. For the evaluation of
ventricular function, patients will receive contrast in the
left ventricle, and measures will be taken with the
patient in the right anterior oblique position. The calcu-
lation of left ventricular ejection fraction will be made
according to the Dodge formula.
For the angiographic study of the coronary arteries, 5
views of the left coronary artery and 2 of the right coron-
ary artery will be obtained. These effects allow a clear
assessment of each coronary artery, thus forming 4 pairs
of perpendicular incidence suitable for biplane analysis.
Nitrates or other vasoactive drugs will be available
when needed. The same sequence of arteriographic pro-
jections, field X-ray, and size of catheters will be followed
in each patient and similarly in subsequent examinations.
These conditions will be crucial for the accurate assess-
ment of the artery after 5 years of follow-up.
Possible changes in the lumen of the coronary arteries
will be assessed visually and quantitatively. Two
experienced observers are blinded to the identity of the
patient during both tests and also for the sequence of
films at the beginning and end of the study.
The pair of films, the initial and final will be seen both
side by side with 5 times magnification in a projector
system adapted for this analysis.
To evaluate the second angiogram, 2 incidences will
be selected of a good quality at the same point in the
cardiac cycle as on the first angiogram of each coronary
artery studied. Based on direct visual comparison of the
coronary arteries, by consensus, the arteries will be
rated as unchanged, definitely changed, or possibly
changed. For possibly changed, a third frame will be
selected for each view from each film.
Coronary artery calcium scan
It is assumed that the presence of calcium in the wall of
the coronary arteries is a strong indicator for the diag-
nosis of coronary artery disease [30,31]. Previous studies
using electron-beam computed tomography (EBCT)
have suggested that EBCT has great potential for nonin-
vasive quantification of calcium in the coronary arteries
[32,33]. Furthermore, CAD is also related to the pre-
sence of calcium with luminal narrowing of coronary
arteries and correlates with clinical, angiographic, and
pathology data [34,35].
However, this method of investigation was unable to
precisely define the percentage of luminal narrowing
based only on the presence of calcium in the wall of
artery.
Recent studies have focused attention on the uncer-
tainties of visual estimates of the percentage of luminal
narrowing compared with angiography, the difficulty of
making visual estimates, and therefore their reproduci-
bility [36,37], their predictive value, changes in the flow,
and also in flow reserve [38,39].
Thus, to prevent this methodological bias, we plan to
evaluate the presence of calcium in the arterial wall by
performing a coronary artery calcium scan using EBCT
at baseline and after 5 years of follow-up and to corre-
late these findings with angiographic data at the begin-
ning and end of the study. This procedure can identify
possible luminal narrowing and also eliminate any meth-
odological flaw, because it compares similar examina-
tions at the beginning and end of the study.
Myocardial scintigraphy
To evaluate the presence of myocardial ischemia, even
in the absence of coronary epicardial vessels, all patients
will undergo myocardial scintigraphy during exercise at
baseline and at the end of the study. The images of
myocardial scintigraphy will be acquired through the
tomographic technique (SPECT - Single Photon Emis-
sion Computed Tomography), synchronized with an
Table 1 Schedule of measurements
S 6 12 18 24 30 36 42 48 54 60
mmmmmmmmmm
History/events X X X X X X X X X X X
Physical examination X X XXXX
Symptom assessment X X X X X X X X X X X
Routine laboratory X X X XXXX
Electrocardiography X X X XXXX
Echocardiography X X XXXX
Stress MPI X X X
Medications X X X X X X X X X X X
Angiograms X X
CAC-Scan X X
Arterial stiffness X X
Resources utilization X
Quality of life X X
Work status X X
Serious adverse events Continuous X
Abbreviations: S = baseline; 6m = 6 month after study entry; 12 m to 60 m
denotes months after study entry. Stress MPI=Stress myocardial perfusion
imaging, CAC-Scan=Coronary-artery calcium (CAC) scan.
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Page 3 of 7electrocardiographic signal (gated), which allows for the
simultaneous assessment of myocardial perfusion and a
quantitative parameter of ventricular function, by using
the 99mTc-Sestamibi (2-methoxy-isobutyl-isonitrile
marked with technetium-99 m) as a myocardial perfu-
sion marker.
With the patient under resting conditions, 740 MBq of
99 mTc-Sestamibi will be endovenously administrated to
the patient, and the acquisition of images will be per-
formed 60 to 90 minutes after the injection. Near the
end of the stress test, 740 MBq of 99 mTc-Sestamibi
will be introduced, and the patient will be stimulated to
continue exercising for at least 1 minute, if possible.
After the recovery stage, data will be recorded, and the
patient will be placed under the gamma-chamber detec-
tor so that images can be obtained.
The acquisition of images will be performed in a noncir-
cular orbit, starting from a RAO 45° projection to LPO 45°
projection, thus completing 180° scan for tomographic
images, at 64 frames in a 64 × 64 matrix (1 detection every
2.8° with a duration of 30s), using an energy of 140 keV
windows. No coefficient of spreading attenuation or
correction will be used. The images will be prefiltered with
a 2-dimensional Butterworth filter with order 5, cutoff fre-
quency of 0.6 Nyquist, and reconstructed through the
iterative method (5 iterations) in a Sun computer, Ultra 60
model, through the AUTO SPECT + Instill 5.0 software,
according to the existing recommendations [40,41]. The
analysis of ejection fraction will be performed using
AUTO QUANT 4.21 software. For the quantification of
ischemic myocardium, a semi-quantitative assessment will
be performed of a 17-segment model (short axis and long
vertical axis will be separated into 6 segments in the apical,
middle, and basal sections of the short axis, and in 2 apical
segments in the long vertical section), retrospectively ana-
lyzed by at least 3 experienced observers, without any
knowledge of clinical, ergometric, and cinecoronario-
graphic data [41].
At the beginning of the study and at the end of
follow-up, perfusion images will be analyzed and quanti-
fied through the 5-point semi-quantitative scoring
system: 0 (normal), 1 (discreet reduction in captation), 2
(moderate reduction in captation), 3 (significant reduc-
tion in captation of radioisotopes), 4 (apparent absence
of detectable captation at the follow-up).
T h ee x e r c i s es c o r es u m m e d( E S S )i n d e xw i l lb e
acquired by summing the scores of 17 follow-ups of
exercise stress test imaging [42]. The resting score
summed (RSS) index will be obtained in the same way,
by summing the scores of 17 follow-ups of the image of
captation at each examination of rest. To estimate the
reversibility of the defect, the difference in the score
summed (DSS) index will be calculated through the sub-
traction of the ESS from the RSS index.
Doppler echocardiography
Changes in myocardial contractility in both systole and
diastole are identified by Doppler-echocardiography.
Thus, to assess the presence of variation in myocardial
thickness or systolic-diastolic movements even in the
absence of coronary epicardial vessels, all patients will
undergo echocardiography at baseline and at the end of
the study.
Patients will undergo examination with commercially
available 2-dimensional echocardiographic ATL equip-
ment, with an electronic transducer of 2.5 mHz. Inter-
mediate examinations during follow-up will not be
considered. For study purposes, echocardiographic
patients will be free of medications at the beginning and
end of the study. Normal LV systolic function will be
considered >50%.
For the echocardiographic examination, patients will
be examined while in the left lateral position with a
slight rotation of the thorax, and standardized apical
and parasternal approaches. Echocardiographic records
follow the recommendations of the American Society of
Echocardiography.
The relaxation time of the left ventricle (TRIVE) will
be determined by the simultaneous recording of intraca-
vitary blood flow on Doppler measured at the end of
the closure of the aortic and mitral valve opening, corre-
sponding to the beginning of the E-wave.
The E-wave deceleration time is calculated by the time
interval between the peak E-wave and the intersection of
this line with that at baseline.
The tests will be analyzed by 3 observers. The first
observer will assess the measures twice and a second
observer once. The third observer will be available to
resolve doubts. Interobserver and intraobserver variabil-
ity will be identified and corrected by consensus.
Arterial stiffness
All patients will be evaluated for vascular stiffness at base-
line and at the end of follow-up. Measurement of arterial
stiffness is considered to be particularly interesting in the
proposed scenario since the absence of atherosclerotic
obstructions indicated by conventional angiograms, and
confirmed by coronary artery calcium scan, empowers in
significance prospective changes in arterial mechanical
properties. It is thus conceivable that this will be a useful
tool in informing the development and possible progres-
sion of atherosclerotic disease. Arterial stiffness can be
assessed noninvasively by different methodologies. The
measurement of aortic pulse wave velocity is generally
accepted as a very reliable method since it is simple, non-
invasive, and reproducible, and can be compared periodi-
cally being supported by the greatest number of
epidemiological studies for its predictive value for initia-
tion or progression of coronary artery disease.
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Page 4 of 7Briefly, wave forms will be obtained transcutaneously
over the radial or common carotid artery and the right
femoral artery, and the time delay is measured between
the feet of the 2 wave forms.
Laboratory measurements
The following laboratory measurements will be recorded
on the same day: HbA1c (agarose electrophoresis; nor-
mal value <6%; Hyrys Hydrasys, Sebia, France); serum
total cholesterol, HDL cholesterol, and triglycerides
(enzymatic colorimetry; Hitachi 912; Roche Diagnostic);
creatinine (colorimetry; Kone Optima; Thermolab Sys-
tems, Helsinki, Finland); and urinary albumin excretion
rate on a 24-h urine collection (laser immunonephelo-
metry; BN100; Dade-Behring, Paris, France). LDL cho-
lesterol will be calculated according to the Friedwald
formula and creatinine clearance according to the Cock-
roft and Gault formula.
Genetic Analysis
All patients will have genomic DNA extracted from
whole blood at study enrollment. Genomic DNA will be
extracted following a standard salting-out protocol.
Assuming that genetic factors will be responsible, at
least in part, for different outcomes of diabetic patients
regarding coronary artery disease progression, we plan
to use this resource for genetic risk stratification of the
studied individuals. Initially, our protocol will follow
previously described loci associated with different inter-
mediate phenotypes of coronary artery disease pathology
(ie, lipid levels, diabetes, atherosclerosis phenotypes,
hypertension/blood pressure), hypothesizing that they
will also modulate the risk of coronary disease progres-
sion in this particular cohort.
Statistical analyses
All data will be expressed as means ± SD. Differences
between the data of patients for clinical and biological
characteristics and basal hemodynamic parameters were
analyzed by the nonparametric Mann-Whitney test.
Changes in hemodynamic parameters at baseline and
the end of follow-up will be analyzed with the paired
Student t test. Comparisons between coronary artery
dimensions at baseline and the end of the study will be
made by 2-way ANOVA with repeated measures for
experimental condition factor followed by the Fisher
protected least-significance difference test.
The Spearman test will be used to find the correlates
of coronary endothelium-dependent vasoreactivity. Due
to its skewed distribution, urinary albumin excretion
rate will be log transformed in the correlation analyses.
A backward linear multiple regression will be performed
to find the independent predictors for endothelium-
dependent coronary vasoreactivity. Statistical signifi-
cance is assumed when P < 0.05.
Discussion
The MASS IV-DM trial is a study designed to include
diabetic patients with suspected myocardial ischemia
whose conventional angiogram showed coronary arteries
to be angiographically normal.
Even if diabetes has been implicated as the main causal
factor in the development of coronary atherosclerosis, the
question that arises is what are the protective mechanisms
of this so-called micro- and macrovascular disease. On the
other hand, the mechanisms associated with coronary
artery disease are likely multifactorial, including hyperten-
sion, abdominal obesity, and plurimetabolic syndrome;
diabetes plays an important role in this scenario.
Patients with CAD without diabetes compared with
diabetic patients have coronary atherosclerosis that is
more advanced, and rates of ventricular dysfunction and
cardiac events are higher. Additionally, the prognosis of
CAD is less favorable in patients with diabetes than
their nondiabetic counterparts; mortality after infarction
is higher in diabetic patients and is particularly high
among women.
Few studies discuss in depth the occurrence of major
cardiovascular events in long-term follow-up in patients
with type 2 diabetes with angiographically normal cor-
onary arteries.
The MASS IV-DM Trial is a great opportunity to
address all these issues, and it will add relevant informa-
tion to this field.
Ethical Considerations
The MASS IV-DM Trial is conducted in accordance
with the principles of the Declaration of Helsinki and
with laws and regulations of our country. The Ethics
Committee of the Heart Institute of the University of
São Paulo, Brazil approved the study protocol. The
attending physician obtained written informed consent
from the study participants.
Final Considerations
The MASS IV-DM trial is designed to include diabetic
patients with clinically suspected myocardial ischemia in
whom conventional angiography shows angiographically
normal coronary arteries. The idea that diabetes mellitus
is a micro- and macrovascular disease leads us to reflect
on the difficulties of comprehending the pathophysiolo-
gical mechanisms of the disease. The question that
arises is what is the protective mechanism of vascular
involvement? The result of extensive research including
angiographic follow-up by several methods, vascular
reactivity, pro-thrombotic mechanisms, genetic and
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Page 5 of 7biochemical studies may facilitate this understanding
and lead to more specific studies for the prevention of
so-called micro- and macrovascular disease.
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